3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
13
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Sarcoma
1
Refractory Solid Tumors
1
Liposarcoma
1
HR+HER2- Breast Cancer
1
Carcinoma, Transitional Cell
1
Interventions
Bevacizumab
35
durvalumab
23
atezolizumab
22
Nivolumab
20
lenvatinib
19
tremelimumab
16
Specimen Handling
14
Magnetic Resonance Spectroscopy
12
sintilimab
11
pembrolizumab
9
Ipilimumab
9
tislelizumab
7
Sorafenib
7
cabozantinib
5
X-Rays
5
Immunoglobulin G
5
Disulfides
5
Cyclophosphamide
5
regorafenib
4
Radiotherapy
4
Radiosurgery
4
Radiation
4
Oxaliplatin
4
Immunotherapy
4
Ethiodized Oil
4
fludarabine
3
donafenib
3
Surgical Procedures, Operative
3
Folfox protocol
3
Fluorouracil
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
eribulin
×
90 days
×
Clear all
No trials found.